
Palisade Bio (PALI) Stock Forecast & Price Target
Palisade Bio (PALI) Analyst Ratings
Bulls say
Palisade Bio Inc is positioned favorably due to its advancement of PALI-2108, a promising candidate for treating autoimmune diseases, particularly ulcerative colitis (UC), where there is a significant unmet medical need. The company has reported encouraging pre-clinical data showcasing PALI-2108’s anti-inflammatory effects and tolerability, specifically highlighting its anti-TNF activity and substantial reductions in inflammatory markers. With the stock showing a positive upward trend and the prospect of addressing a niche market for oral PDE4 therapies, the outlook for Palisade Bio's stock appears strong based on these developments.
Bears say
Palisade Bio Inc faces significant financial challenges, including a lack of commercial infrastructure that hampers its ability to bring products to market. The company is currently not profitable and may require additional capital, which raises concerns about potential dilution for existing investors. Furthermore, both the company and its auditors have expressed substantial doubt regarding its ability to continue as a going concern, exacerbating the already precarious financial situation.
This aggregate rating is based on analysts' research of Palisade Bio and is not a guaranteed prediction by Public.com or investment advice.
Palisade Bio (PALI) Analyst Forecast & Price Prediction
Start investing in Palisade Bio (PALI)
Order type
Buy in
Order amount
Est. shares
0 shares